Articles
Bayer and Alnylam drugs among highlights at ESC

Bayer and Alnylam drugs among highlights at ESC

New drug candidates in heart failure and cholesterol control, plus insights into healthy lifestyle habits, are among the highlights from the London conference, writes Kevin Grogan.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D